Qian Jiang1,2, Robert Peter Gale3. 1. Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11 Xizhimen South Street, Beijing, 100044, China. jiangqian@medmail.com.cn. 2. Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People's Republic of China. jiangqian@medmail.com.cn. 3. Division of Experimental Medicine, Department of Medicine, Haematology Research Centre, Imperial College London, London, UK.
Abstract
PURPOSE: Explore molecular monitoring patterns of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitors therapy in China and identify variables associated with monitoring patterns. METHODS: Non-interventional, cross-sectional study using questionnaires distributed to persons with CML and answered anonymously. RESULTS: A total of 819 respondents in chronic phase outside clinical trials were evaluable; 477 respondents (58 %) were male. Median age was 41 years (range 18-88 years). A total of 609 (74 %) respondents received a TKI <1 year after diagnosis and 665 (81 %) were on a branded TKI. Median TKI therapy duration was 3 years (range <1-13 years). A total of 255 (31 %) respondents had a molecular test every 3 months, and 280 (34 %), every 6 months. Multivariate analyses showed that older age, starting TKI therapy >1 year after diagnosis and generic TKI use were associated with deviation from recommended monitoring frequency (both every 3 months and every 3 or 6 months). In addition, TKI therapy duration >3 years and imatinib use were associated with under-testing every 3 months. Rural household registration was associated with less testing at every 3 or 6 months. The most commonly stated reasons for under-testing were no requirement by physician (60 %), followed by cost (19 %), no necessity (10 %) and no eligible lab nearby (10 %). CONCLUSIONS: Many Chinese with chronic phase CML receiving TKI therapy do not have response monitoring compliant with recommended guidelines. Older age, financial burden and physician non-adherence to guideline recommendations are associated with low monitoring frequencies.
PURPOSE: Explore molecular monitoring patterns of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitors therapy in China and identify variables associated with monitoring patterns. METHODS: Non-interventional, cross-sectional study using questionnaires distributed to persons with CML and answered anonymously. RESULTS: A total of 819 respondents in chronic phase outside clinical trials were evaluable; 477 respondents (58 %) were male. Median age was 41 years (range 18-88 years). A total of 609 (74 %) respondents received a TKI <1 year after diagnosis and 665 (81 %) were on a branded TKI. Median TKI therapy duration was 3 years (range <1-13 years). A total of 255 (31 %) respondents had a molecular test every 3 months, and 280 (34 %), every 6 months. Multivariate analyses showed that older age, starting TKI therapy >1 year after diagnosis and generic TKI use were associated with deviation from recommended monitoring frequency (both every 3 months and every 3 or 6 months). In addition, TKI therapy duration >3 years and imatinib use were associated with under-testing every 3 months. Rural household registration was associated with less testing at every 3 or 6 months. The most commonly stated reasons for under-testing were no requirement by physician (60 %), followed by cost (19 %), no necessity (10 %) and no eligible lab nearby (10 %). CONCLUSIONS: Many Chinese with chronic phase CML receiving TKI therapy do not have response monitoring compliant with recommended guidelines. Older age, financial burden and physician non-adherence to guideline recommendations are associated with low monitoring frequencies.
Authors: Lei Chen; Annie Guérin; Jipan Xie; Eric Q Wu; Andrew P Yu; Solveig G Ericson; Elias Jabbour Journal: Curr Med Res Opin Date: 2012-11-05 Impact factor: 2.580
Authors: Stuart L Goldberg; Lei Chen; Annie Guerin; Alexander R Macalalad; Nathan Liu; Michael Kaminsky; Solveig G Ericson; Eric Q Wu Journal: Curr Med Res Opin Date: 2013-06-21 Impact factor: 2.580
Authors: N C P Cross; H E White; D Colomer; H Ehrencrona; L Foroni; E Gottardi; T Lange; T Lion; K Machova Polakova; S Dulucq; G Martinelli; E Oppliger Leibundgut; N Pallisgaard; G Barbany; T Sacha; R Talmaci; B Izzo; G Saglio; F Pane; M C Müller; A Hochhaus Journal: Leukemia Date: 2015-02-05 Impact factor: 11.528